A documentation-first CJC-1295 DAC 5 mg profile combining standardized compound identity, published early human research and current FDA safety context.
PubChem lists CJC-1295 as CID 91971820 and describes it as a maleimido derivative of human growth hormone-releasing factor 1-29, with molecular formula C165H269N47O46 and molecular weight about 3647.2 g/mol.1
A published 2006 study evaluated CJC-1295 in healthy adults using randomized, placebo-controlled, double-blind ascending-dose trials. That study belongs to the compound evidence base and should not be interpreted as testing the MedCore 5 mg presentation.2
Unlike many research peptides, CJC-1295 has published early human data, but that does not remove important limitations around clinical evidence and safety.
A 2006 paper reported two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults examining CJC-1295 pharmacokinetics, pharmacodynamic effects and safety. The study evaluated effects on growth hormone and IGF-I secretion.2
PubChem lists CJC-1295 as CID 91971820 and provides formula, molecular weight and structural identifiers.1
FDA states that compounded CJC-1295 may raise immunogenicity and peptide-impurity concerns and notes serious adverse events including increased heart rate and systemic vasodilatory reaction.3
Published compound-level human data do not establish that the MedCore CJC-1295 DAC 5 mg presentation is an approved medicine, clinically equivalent product or proven treatment.
The MedCore portfolio identifies CJC-1295 DAC as a 5 mg research presentation. Product-specific quality claims should be supported by MedCore batch documentation rather than inferred from scientific literature.
Only verified product data belongs here. Batch, purity, route and laboratory information should be added only from corresponding MedCore documentation.
Scientific literature and product-specific quality records are intentionally separated so human-study findings are not converted into unverified product claims.
Strength-specific documentation preview for the MedCore CJC-1295 DAC research presentation.
These images are presented as sample product documentation and should not be interpreted as independently verified analytical certification. Product identity, batch data and analytical claims should be checked against original laboratory records.
Internal links connect related entities without duplicating the same scientific narrative.
Short answers align the page with compound identity, human evidence and current regulatory context.
The evidence layer combines a standardized chemical record, a peer-reviewed human study and current FDA safety context. Last reviewed 2 September 2026.
Compound identity, molecular formula and molecular weight.
Open PubChem source ↗Published randomized, placebo-controlled early human research in healthy adults.
Open PubMed source ↗FDA safety context and statement that CJC-1295 clinical data are limited.
Open FDA source ↗Review the quality framework or contact MedCore for product-specific documentation.
